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Chronic lung infections are the leading cause of death in subjects with cystic fibrosis 
(CF). To date, sputum culture is the most common technique for the diagnosis of lung 
infections in adult CF subjects. However, it requires several days or longer to obtain 
culture results. Therefore, a rapid diagnostic technique for lung infections would 
significantly improve CF healthcare. During recent decades, exhaled breath analysis has 
attracted interest as a rapid and non-invasive tool for the diagnosis of non-communicable 
diseases such as cancers and heart diseases. However, there is limited progress in the 
diagnosis of infectious diseases such as lung infections in CF subjects using volatile 
organic compounds (VOCs) as biomarkers of infection. 
In this study, sputum and breath samples were collected from CF subjects and healthy 
controls (only breath) and profiled for VOCs using comprehensive two-dimensional gas 
chromatography time-of-flight mass spectrometry (GC×GC–TOFMS). Multivariate 
analyses (e.g. principal component analysis and linear discriminant analysis (LDA)) were 
then performed to allow differentiation between: (i) CF subjects and healthy controls and 
(ii) CF subjects with/without Pseudomonas aeruginosa infections and those with no 
known lung infections as confirmed using their sputum culture results. This study 
identified a set of 16 VOCs which allowed differentiation between CF subjects and 
healthy controls. In particular, healthy controls were classified with 98% accuracy, while 
CF subjects were classified with 92% accuracy. It is important to note that all of the CF 
subjects that participated in this study are significantly different from control groups, not 
only in terms of their lung infection status but also in terms of numerous other factors 
(e.g. diet, lifestyle, medications, and other health complications). These factors can also 
impact the breath profiles obtained from the study group (CF subjects). 
The analysis of matching sputum and breath samples collected from CF subjects provided 
a set of 24 core VOCs common between both sample types. LDA performed using these 
VOCs provided accurate classification of CF subjects according to their lung infection 
status (i.e. CF subjects with/without Pseudomonas aeruginosa infection). The outcome 
of LDA also showed that these common VOCs have better classification accuracy than 
the entire profile of the VOCs detected in sputum and breath samples. Finally, the 
comparison of breath profiles between CF subjects with/without Pseudomonas 
aeruginosa infection and those with no known lung infection showed that it is also 
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possible to allow differentiation between these contrasting groups using breath VOCs 
profiles. 
